• About us
• Contact

Advertisement

Organisation › Details

AC Immune S.A. (Nasdaq: ACIU)

AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments. *

 

	Start	2003-02-01 established
	Industry	CNS drug (neurological drug)
	Industry 2	crenezumab
	Person	Roberts, Christopher (Chris) (AC Immune 202401– promoted to CFO joined 2019)
	Region	Lausanne VD
	Country	Switzerland
	City	1015 Lausanne VD
	Tel	+41-21-3459121
		Address record changed: 2024-01-05
Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	CHF
	Annual sales	14,801,000 (revenue, total, consolidated (2023) 2023-12-31)
	Profit	-54,233,000 (2023-12-31)
	Cash	78,494,000 (2023-12-31)
		* Document for »About Section«: AC Immune S.A.. (6/27/23). "Press Release: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease". Lausanne.
		Record changed: 2024-09-17

Advertisement

More documents for AC Immune S.A. (Nasdaq: ACIU)

• [1] AC Immune S.A.. (5/13/24). "Press Release: AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease". Osaka, Cambride, MA & Lausanne....
• [2] AC Immune S.A.. (12/15/23). "Press Release: AC Immune Announces Pricing of Underwritten Offering of Common Shares". Lausanne....
• [3] AC Immune S.A.. (12/15/23). "Press Release: AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO". Lausanne....
• [4] AC Immune S.A.. (6/27/23). "Press Release: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease". Lausanne....
• [5] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
• [6] AC Immune S.A.. (7/27/21). "Press Release: AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH". Lausanne....
• [7] Oxurion N.V.. (10/13/20). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Financial Officer". Leuven & Boston, MA....
• [8] AC Immune S.A.. (8/5/20). "Press Release: AC Immune Reports Q2 2020 Financial Results and Provides Business Update". Lausanne....
• [9] AC Immune S.A.. (3/23/20). "Press Release: AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership". Lausanne....
• [10] AC Immune S.A.. (9/20/19). "Press Release: AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.